These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 14522887)

  • 1. Tumor promotion by Mdm2 splice variants unable to bind p53.
    Fridman JS; Hernando E; Hemann MT; de Stanchina E; Cordon-Cardo C; Lowe SW
    Cancer Res; 2003 Sep; 63(18):5703-6. PubMed ID: 14522887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
    Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
    Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis.
    Steinman HA; Burstein E; Lengner C; Gosselin J; Pihan G; Duckett CS; Jones SN
    J Biol Chem; 2004 Feb; 279(6):4877-86. PubMed ID: 14612455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RING domain of Mdm2 can inhibit cell proliferation.
    Dang J; Kuo ML; Eischen CM; Stepanova L; Sherr CJ; Roussel MF
    Cancer Res; 2002 Feb; 62(4):1222-30. PubMed ID: 11861407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis.
    Alt JR; Greiner TC; Cleveland JL; Eischen CM
    EMBO J; 2003 Mar; 22(6):1442-50. PubMed ID: 12628936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
    Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
    Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative and aberrant splicing of MDM2 mRNA in human cancer.
    Bartel F; Taubert H; Harris LC
    Cancer Cell; 2002 Jul; 2(1):9-15. PubMed ID: 12150820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
    Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
    Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells.
    Kraus A; Neff F; Behn M; Schuermann M; Muenkel K; Schlegel J
    Int J Cancer; 1999 Mar; 80(6):930-4. PubMed ID: 10074928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mdm2 Splice isoforms regulate the p53/Mdm2/Mdm4 regulatory circuit via RING domain-mediated ubiquitination of p53 and Mdm4.
    Fan C; Wang X
    Cell Cycle; 2017 Apr; 16(7):660-664. PubMed ID: 28166445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms.
    Matsumoto R; Tada M; Nozaki M; Zhang CL; Sawamura Y; Abe H
    Cancer Res; 1998 Feb; 58(4):609-13. PubMed ID: 9485008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
    Eischen CM; Alt JR; Wang P
    Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer.
    Sigalas I; Calvert AH; Anderson JJ; Neal DE; Lunec J
    Nat Med; 1996 Aug; 2(8):912-7. PubMed ID: 8705862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 splice variants and their therapeutic implications.
    Harris LC
    Curr Cancer Drug Targets; 2005 Feb; 5(1):21-6. PubMed ID: 15720186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas.
    Tamborini E; Della Torre G; Lavarino C; Azzarelli A; Carpinelli P; Pierotti MA; Pilotti S
    Int J Cancer; 2001 Jun; 92(6):790-6. PubMed ID: 11351297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification of the MDM2 gene, but not expression of splice variants of MDM2 MRNA, is associated with prognosis in soft tissue sarcoma.
    Bartel F; Meye A; Würl P; Kappler M; Bache M; Lautenschläger C; Grünbaum U; Schmidt H; Taubert H
    Int J Cancer; 2001 May; 95(3):168-75. PubMed ID: 11307150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p76(MDM2) inhibits the ability of p90(MDM2) to destabilize p53.
    Perry ME; Mendrysa SM; Saucedo LJ; Tannous P; Holubar M
    J Biol Chem; 2000 Feb; 275(8):5733-8. PubMed ID: 10681559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 splice variants predominantly localize to the nucleoplasm mediated by a COOH-terminal nuclear localization signal.
    Schuster K; Fan L; Harris LC
    Mol Cancer Res; 2007 Apr; 5(4):403-12. PubMed ID: 17426254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A deficiency in Mdm2 binding protein inhibits Myc-induced B-cell proliferation and lymphomagenesis.
    Odvody J; Vincent T; Arrate MP; Grieb B; Wang S; Garriga J; Lozano G; Iwakuma T; Haines DS; Eischen CM
    Oncogene; 2010 Jun; 29(22):3287-96. PubMed ID: 20305689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of human p53 activity and cell localization by alternative splicing.
    Ghosh A; Stewart D; Matlashewski G
    Mol Cell Biol; 2004 Sep; 24(18):7987-97. PubMed ID: 15340061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.